Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 11/20 | 0.45 |
| ▸ | NPC1 | O15118 | 10/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14872322 | 0.80 | SMN1; SMN2 (0.55) | SMN1; SMN2RAB9ANPC1HPGDKDM4A | |
| SCHEMBL12141900 | 0.80 | HSD11B1 (0.40) | SMN1; SMN2RAB9ANPC1HPGDALDH1A1 | |
| SCHEMBL13466400 | 0.78 | HTR2C (0.48) | SMN1; SMN2HSP90AA1HSP90AB1RAB9ANPC1 | |
| SCHEMBL3076069 | 0.77 | SMN1; SMN2 (0.55) | SMN1; SMN2RAB9ANPC1HPGDTP53 | |
| SCHEMBL16379733 | 0.77 | SMN1; SMN2 (0.55) | SMN1; SMN2RAB9ANPC1HPGDKDM4A | |
| SCHEMBL19473337 | 0.75 | SMN1; SMN2 (0.65) | SMN1; SMN2HSP90AA1HSP90AB1RAB9ANPC1 | |
| SCHEMBL10255135 | 0.75 | SMN1; SMN2 (0.65) | SMN1; SMN2HSP90AA1HSP90AB1RAB9AHPGD | |
| SCHEMBL8819862 | 0.75 | HSP90AA1 (0.47) | SMN1; SMN2HSP90AA1HSP90AB1RAB9ANPC1 | |
| SCHEMBL12141908 | 0.74 | ALDH1A1 (0.57) | SMN1; SMN2RAB9AMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL19651845 | 0.73 | HSP90AA1 (0.48) | SMN1; SMN2HSP90AA1HSP90AB1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | SMN1; SMN2 2126/4885HSP90AA1 2923/4885HSP90AB1 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.